CADx Medical Systems can now market its Second Look CAD product in the U.S., following FDA approval of the system. The subsidiary of Shire Pharmaceuticals Group is preparing to market the product to hospitals, clinics, and
CADx Medical Systems can now market its Second Look CAD product in the U.S., following FDA approval of the system. The subsidiary of Shire Pharmaceuticals Group is preparing to market the product to hospitals, clinics, and mammography centers across the U.S. The decision follows receipt by the company Nov. 21 of an approvable letter from the regulatory agency. Second Look is based on imaging algorithms used by the U.S. military to automatically recognize targets. Approved for both screening and diagnostic use, Second Look will be marketed to radiologists as a tool for highlighting the most critical masses and microcalcifications on mammograms. Clinical trials demonstrated that 26.2% of lesions otherwise missed could be detected with Second Look.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.